Insulet to Present at Upcoming Investor Conferences

Rhea-AI Summary

Insulet (NASDAQ: PODD), the leader in tubeless insulin pump technology, announced its participation in three upcoming investor conferences: The 6th Annual Wolfe Research Healthcare Conference in New York (November 20, 2024), The Nasdaq 51st Investor Conference in London (December 10, 2024), and The J.P. Morgan 43rd Annual Healthcare Conference in San Francisco (January 14, 2025).

The company's flagship product, the Omnipod 5 Automated Insulin Delivery System, offers a unique tubeless insulin delivery solution that integrates with continuous glucose monitoring, requiring no daily injections or fingersticks, and can be controlled via smartphone in the U.S. Live audio webcasts of the presentations will be available on the company's investor relations website.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time):

• The 6^th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m.
• The Nasdaq 51^st Investor Conference in London on Tuesday, December 10, 2024 at 5:30 a.m.
• The J.P. Morgan 43^rd Annual Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 6:45 p.m.

To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will also be available following the events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241115947479/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

When will Insulet (PODD) present at the Wolfe Research Healthcare Conference in 2024?

Insulet will present at the 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024, at 12:00 p.m. Eastern Time.

What are the key features of Insulet's Omnipod 5 Automated Insulin Delivery System?

The Omnipod 5 System offers tubeless insulin delivery, integrates with continuous glucose monitors, requires no multiple daily injections or fingersticks, and can be controlled by a compatible smartphone in the U.S. or the Omnipod 5 Controller.

How long can Insulet's Omnipod provide continuous insulin delivery?

The Omnipod provides up to three days of non-stop insulin delivery without the need to see or handle a needle.

Which investor conferences will Insulet (PODD) attend between November 2024 and January 2025?

Insulet will attend the Wolfe Research Healthcare Conference (Nov 20), the Nasdaq 51st Investor Conference (Dec 10), and the J.P. Morgan 43rd Annual Healthcare Conference (Jan 14, 2025).